Anna Durbin
Infectious Disease · Baltimore, MDNPI 1326089541
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $42,255 of the $45,266 with a category attached, or 93.3%. 6 manufacturers reported payments, led by Merck at 33.8% of the total. Among infectious disease clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 37 payments — averaging $1223.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$15K
- Emergent Biosolutions Inc.$11K
- Valneva USA, Inc.$9K
- Valneva Austria GmbH$6K
- Roche Diagnostics International Ltd$4K
- Modernatx, Inc.$1K
Across 5 payments — averaging $70,972 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$355K
What the payments were for
- Consulting fees$42,25593%
- Travel & lodging$2,2735%
- Food & beverage$7382%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 16 | $15,282 |
| Emergent Biosolutions Inc. | 12 | $10,509 |
| Valneva USA, Inc. | 5 | $8,575 |
| Valneva Austria GmbH | 2 | $6,300 |
| Roche Diagnostics International Ltd | 1 | $3,600 |
| Modernatx, Inc. | 1 | $1,000 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- POC ACCU-CHEK Safe-T-Pro Lancets$3,600
- V181$1,000
How this compares
$45,266 in reported general payments places this provider in the 90th percentile of 289 infectious disease providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 14 | $53,407 |
| Amlodipine Besylate | 11 | $2 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Baltimore
- Robert RedfieldBaltimore$779K
- Luciana BorioBaltimore$671K
- Mark SulkowskiBaltimore$240K
- Jonathan ZenilmanBaltimore$202K
- Robert EdelmanBaltimore$125K
- Kjell WibergBaltimore$113K
- Christine DurandBaltimore$53K
- Myron LevineBaltimore$51K
- Robert BollingerBaltimore$50K
- Richard BergBaltimore$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.